Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Beijing Tiantan Biological Products EBITDA Margin %?
Beijing Tiantan Biological ProductsSHSE:600161 75 EBITDA Margin % is 19.71% as of Mar. 2026, which is 46% below its 10-year median of 36.29. GuruFocus rates SHSE:600161 with a GF Score™ of 75/100 and a GF Value™ of ¥23.94 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 939 Biotechnology companies, Beijing Tiantan Biological Products ranks better than 87.54% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Beijing Tiantan Biological Products EBITDA Margin % Related Terms
Beijing Tiantan Biological Products EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600161 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Beijing Tiantan Biological Products's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tiantan Biological Products EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Tiantan Biological Products's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Beijing Tiantan Biological Products's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tiantan Biological Products (SHSE:600161) has a EBITDA Margin % of 19.71% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Beijing Tiantan Biological Products and its competitors. This is 46% below median its historical median of 36.29. Over the past decade, Beijing Tiantan Biological Products' EBITDA Margin % has ranged from 27.48 to 70.69. According to the industry distribution chart, Beijing Tiantan Biological Products ranks #117 out of 939 companies in the Biotechnology industry, placing it in the top 12.5%.
Is Beijing Tiantan Biological Products' EBITDA Margin % too high?
Beijing Tiantan Biological Products' current EBITDA Margin % of 19.71% is 46% below median its 10-year median of 36.29. Over the past 10 years, this metric has ranged from a low of 27.48 to a high of 70.69. Based on the distribution chart, Beijing Tiantan Biological Products ranks #117 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Tiantan Biological Products has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tiantan Biological Products' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Tiantan Biological Products ranks #117 out of 939 companies for EBITDA Margin %. This places Beijing Tiantan Biological Products in the top 13% of its industry — outperforming the majority of peers. Historically, Beijing Tiantan Biological Products' own EBITDA Margin % has ranged from 27.48 to 70.69 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Beijing Tiantan Biological Products and its competitors. Beijing Tiantan Biological Products's current EBITDA Margin % is 19.71%, which is 46% below median its own 10-year median of 36.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tiantan Biological Products stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products (SHSE:600161) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥23.94, compared to a current price of ¥12.95 — trading 45.9% below its estimated fair value. The current EBITDA Margin % is 19.71%, which is 46% below median its 10-year median of 36.29. Beijing Tiantan Biological Products' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Beijing Tiantan Biological Products (SHSE:600161), the current EBITDA Margin % is 19.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tiantan Biological Products (SHSE:600161) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products stock appears to be undervalued.
The current stock price of ¥12.95 is trading 45.9% below its estimated GF Value™ of ¥23.94.
GuruFocus considers Beijing Tiantan Biological Products to be Significantly Undervalued.
Key valuation signals for SHSE:600161:
EBITDA Margin %: 19.71% (46% below median its 10-year median of 36.29)
GF Value™: ¥23.94 vs. price of ¥12.95 (45.9% below fair value)
No single metric tells the full story. See the SHSE:600161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tiantan Biological Products Business Description
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
75GF Score
Get the complete analysis for SHSE:600161
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600161 has been successfully added to your 
